Methods of shielding implantable medical leads and implantable medical lead extensions

Information

  • Patent Grant
  • 10155111
  • Patent Number
    10,155,111
  • Date Filed
    Thursday, July 23, 2015
    8 years ago
  • Date Issued
    Tuesday, December 18, 2018
    5 years ago
Abstract
Shielded sheaths are placed over implantable medical leads and/or implantable medical lead extensions to provide shielding from electromagnetic energy and to prevent heating at the electrodes. The shielded sheaths include insulative bodies with shield layers such as conductive braided wire or conductive foil tubular structures. The shielded sheath may be implanted at the time of implanting the lead and/or lead extension. The shielded sheath may also be implanted at a later time after the lead and/or lead extension has previously been implanted. The shielded sheath may be anchored onto the lead or lead extension.
Description
TECHNICAL FIELD

Embodiments relate to implantable medical leads and implantable medical lead extensions. More particularly, embodiments relate to methods of shielding implantable medical leads and implantable medical lead extensions.


BACKGROUND

Implantable medical systems are used to provide stimulation therapy and/or physiological sensing for patients. The implantable medical system includes a stimulation or sensing device that is implanted at a convenient location. Implantable medical leads are routed between the site of implantation of the device and a target site where stimulation or sensing is to occur. Where the route is lengthy, an implantable medical lead extension is used to traverse a portion of that distance.


The implantable medical leads include one or more electrical contacts located near a proximal end of the lead. Where no extension is needed, the proximal end of the lead is physically connected to the stimulation or sensing device so that the proximal contacts of the lead are electrically coupled to electrical circuitry of the device. For scenarios where the implantable medical lead extension is used, then the proximal end of the lead is physically connected to a distal end of the extension where electrical connectors of the extension are coupled to the electrical contacts of the lead. The proximal end of the extension is physically connected to the stimulation or sensing device so that the proximal contacts of the extension are electrically coupled to electrical circuitry of the device. The leads also include one or more electrodes located near a distal end of the leads. Electrical conductors are present within the lead, and each electrical conductor is connected to a respective electrical contact and electrode to provide an electrical path for stimulation and/or sensed signals. Electrical conductors are also present within the extension, and each electrical conductor is connected to a respective electrical contact and distal connector to provide an electrical path for stimulation and/or sensed signals.


Because the lead and lead-extension combination extends over a significant distance within the body, each electrical conductor within the lead and extension is susceptible to receiving extraneous electromagnetic energy that produces electrical current on the electrical conductor. While most ambient conditions expose the lead and lead extension to insignificant levels of such extraneous electromagnetic energy, certain situations may create levels of extraneous electromagnetic energy that are of concern. An example of such a situation is a magnetic resonance imaging (MRI) scan. The MRI scan utilizes a high energy radio frequency (RF) electromagnetic signal. This RF signal may produce relatively large levels of electrical current on the electrical conductor of the lead and extension when the patient having the implantable medical system that includes the lead and/or lead extension combination undergoes the MRI scan. The relatively large electrical current that results from the high energy RF signal produces heating at the electrodes that may create discomfort and even dangerous tissue damage at the site within the body where the one or more electrodes of the lead are located.


It has been found that a shield layer within the lead reduces the amount of RF energy that reaches the electrical conductors, which in turn reduces the amount of current being coupled onto the electrical conductors and reduces the heating at the electrodes to acceptable levels. The manufacturing process of the lead has been altered to include a shield layer when the lead body is being manufactured by creating an inner jacket over the electrical conductor, then creating the shield layer on the inner jacket, and then creating an outer jacket over the inner jacket. The electrical contacts and electrodes are then installed about the inner jacket and are coupled to the electrical conductor to complete the leads. However, leads and extensions that have been constructed without such shield layers or other protective aspects remain vulnerable to the high levels of RF energy of the MRI scan or other situation.


Additionally, patients having leads and/or extensions implanted that are not designed to be safe during an MRI scan either continue to be ineligible for an MRI scan or must undergo a procedure to replace the lead and/or extension with an MRI compliant version. Replacing the existing lead presents a risk that the new lead will not be positioned in a location that provides therapy that is as effective as with the prior lead. Furthermore, some leads are very difficult to remove, such as leads having a distal paddle that have required surgical procedures for implantation.


SUMMARY

Embodiments address issues such as these and others by adding a shielded sheath over an existing lead or extension. The shielded sheath may then be anchored to the existing lead or extension and to the surrounding body tissue. The shielded sheath may be added to newly implanted leads and/or extensions or to leads and/or extensions that have previously been implanted.


Embodiments provide a method of shielding an implantable medical lead. The method involves providing a sheath that includes a shield layer. The method further involves positioning the sheath that includes the shield layer about an implantable medical lead between a proximal contact on the implantable medical lead and a distal electrode on the implantable medical lead. The method additionally involves anchoring the sheath to the implantable medical lead.


Embodiments provide an apparatus that includes an implantable medical lead having a proximal contact and a distal electrode and also includes a sheath containing a shield layer positioned about the implantable medical lead between the proximal contact and the distal electrode. The apparatus further includes an anchoring structure holding the sheath in a fixed position about the implantable medical lead.


Embodiments provide an implantable medical system that includes an implantable stimulation device and an implantable medical lead having a proximal contact and a distal electrode with the proximal contact being electrically coupled to the implantable stimulation device. The system further includes a sheath containing a shield layer positioned about the implantable medical lead between the proximal contact and the distal electrode and an anchoring structure holding the sheath in a fixed position about the implantable medical lead.


Embodiments provide an apparatus that includes an implantable medical lead extension having a proximal contact and a distal connector block and also includes a sheath containing a shield layer positioned about the implantable medical lead between the proximal contact and a distal end of the implantable medical lead extension. The apparatus further includes an anchoring structure holding the sheath in a fixed position about the implantable medical lead extension.


Embodiments provide a method of shielding an implantable medical paddle lead that involves providing a sheath that includes a shield layer. The method further involves positioning the sheath that includes the shield layer about an implantable medical lead between a proximal contact on the implantable medical lead and a paddle portion of the implantable medical paddle lead, the sheath having an inner diameter that is smaller than a width of the paddle portion of the paddle lead but greater than a diameter of a remainder of the paddle lead such that the sheath is confined by the paddle portion.


Embodiments provide an apparatus that includes an implantable medical paddle lead having a proximal contact and a paddle portion that contains at least one distal electrode, the paddle portion having a width greater than a remainder of the implantable medical paddle lead. The apparatus further includes a sheath containing a shield layer positioned about the implantable medical lead between the proximal contact and the paddle portion, the sheath having an inner diameter that is smaller than a width of the paddle portion of the paddle lead but greater than a diameter of a remainder of the paddle lead such that the sheath is confined by the paddle portion.


Embodiments provide an implantable medical system that includes an implantable stimulation device. The system further includes an implantable medical paddle lead having a proximal contact and a paddle portion that contains at least one distal electrode with the proximal contact being electrically coupled to the implantable stimulation device, the paddle portion having a width greater than a remainder of the implantable medical paddle lead. The system additionally includes a sheath containing a shield layer positioned about the implantable medical lead between the proximal contact and the paddle portion, the sheath having an inner diameter that is smaller than a width of the paddle portion of the paddle lead but greater than a diameter of a remainder of the paddle lead such that the sheath is confined by the paddle portion.





DESCRIPTION OF THE DRAWINGS


FIG. 1 shows an implantable medical system including a lead that has been implanted prior to introduction of a shielded sheath.



FIG. 2 shows the implantable medical system with the shielded sheath installed over the lead.



FIG. 3 shows an example of a procedure that begins with a needle being inserted into an epidural space followed by a guidewire.



FIG. 4 shows the needle being removed from the epidural space while the guidewire remains.



FIG. 5 shows an example of the shielded sheath being inserted into the epidural space by following along the guidewire.



FIG. 6 shows removal of the guidewire from the epidural space while the shielded sheath remains.



FIG. 7 shows an anchor being applied to hold the shielded sheath in place relative to the epidural space.



FIG. 8 shows an implantable medical lead being inserted into the epidural space by passing through the shield sheath.



FIG. 9 shows distal end of the implantable medical lead exiting the distal end of the shielded sheath within the epidural space to reach the stimulation site.



FIG. 10 shows an anchor being applied to hold the lead in place with the shielded sheath relative to the epidural space followed by the proximal end of the lead and shielded sheath being tunneled to the pocket for the implantable medical device.



FIG. 11 shows a set of operations to implant a shielded sheath and an implantable medical lead according to the aspects shown in FIGS. 3-10.



FIG. 12 shows an example of a procedure that begins with an anchor being removed from a lead that is implanted with a distal end in the epidural space and a proximal end of the lead being pulled to the incision site for entry to the epidural space.



FIG. 13 shows an example of the shielded sheath being inserted over the implanted lead.



FIG. 14 shows the shield sheath passing through a scar capsule that surrounds the implanted lead and passing into the epidural space.



FIG. 15 shows an anchor being applied to hold the shielded sheath and lead in place relative to the epidural space.



FIG. 16 shows the proximal end of the lead and shielded sheath being tunneled to the pocket for the implantable medical device.



FIG. 17 shows a set of operations to add a shielded sheath over an implanted lead according to the aspects shown in FIGS. 12-16.



FIG. 18 shows another example of an implantable medical system including a lead extension with shielded sheaths installed over a lead and a lead extension.



FIG. 19 shows an example of a procedure that begins with a lead being tunneled to a bore hole with a distal end of the lead being inserted into the brain to a stimulation site.



FIG. 20 shows an example of a shielded sheath being inserted over the lead.



FIG. 21 shows an example of a second shielded sheath being inserted over a lead extension that has been tunneled and connected to a proximal end of the lead.



FIG. 22 shows the proximal end of the extension and the second shielded sheath being tunneled to the pocket for the implantable medical device.



FIG. 23 shows a set of operations to add a shielded sheath over the implanted lead and to add a second shielded sheath over the implanted extension according to the aspects shown in FIGS. 19-22.



FIG. 24 shows a proximal end of an example of a shielded sheath that may include a connector for engagement with a contact of an implantable medical device.



FIG. 25 shows a proximal end of another example of a shielded sheath that may include a connector with a reduced diameter portion for engagement with a contact of an implantable medical device.



FIG. 26 shows a lateral cross-sectional view of an example of a shielded sheath.



FIG. 27 shows an implantable medical system with the shielded sheath installed over a paddle lead.



FIG. 28 shows the shielded sheath positioned over the paddle lead and being positioned within the epidural space.



FIG. 29 shows a set of operations for one manner of implanting a shielded sheath and an implantable medical paddle lead.



FIG. 30 shows a set of operations for another manner of implanting a shielded sheath and an implantable medical paddle lead.



FIGS. 31A and 31B show sets of operations for ways of implanting a shielded sheath onto a previously implanted medical paddle lead.



FIG. 32 shows an example of an implantable medical system that includes a lead extension, a paddle lead, and first and second shielded sheaths for the paddle lead and lead extension.





DETAILED DESCRIPTION

Embodiments provide shielded sheaths that are installed over leads and/or extensions, whether being implanted or already implanted. The shielded sheath reduces the amount of RF energy that reaches the conductors of the lead and/or extension.



FIG. 1 shows an example where a shielded sheath may be utilized. An implantable medical system 100 that includes an implantable medical device 102 which may be an implantable stimulation device that provides electrical stimulation signals and/or senses physiological signals. The system 100 also includes an implantable medical lead 104 is implanted into a patient 108. In this particular example, the implantable medical system is a spinal cord stimulator where the lead 104 is implanted into a location nearby the spinal cord within the spine 110. The implantable medical device 102 provides electrical stimulation that is delivered through conductors of the lead 104 to the stimulation site. The implantable medical device 102 is implanted within a subcutaneous pocket 114 created during implantation while the lead 104 is tunneled through a path 116 created between the pocket 114 and the entry point 112 to an epidural space during implantation.



FIG. 2 shows an implantable medical system 200 which is identical to the system 100 of FIG. 1 except that a shielded sheath 202 has been placed over the lead 104. The shielded sheath is positioned between the proximal end where the lead 104 connects to the implantable medical device and the distal end where the electrodes 106 are located. The shielded sheath 202 has an insulative shield body with a shield layer 204 within the shield body to isolate the shield layer 204 from the external conditions of the body 108. The shielded sheath provides shielding of RF electromagnetic energy to reduce the amount of RF electromagnetic energy that becomes coupled to the conductors that are within the lead 104 and are connected between the implantable medical device 102 and the electrodes 106.



FIG. 26 shows a lateral cross-sectional view of an example 2600 of the shielded sheath 202. In the shielded sheath 2600, there is an insulative shield body 2602 that defines a lumen 2606 where the lead 104 or a lead extension may pass through. The insulative body may be constructed of various biocompatible materials including various polymers, urethanes such as the PurSil® thermoplastic silicone-polyether-urethane of the Koninklijke DSM N.V. Corporation of the Netherlands, and other silicones. A shield layer 2604 is also present and is embedded within the insulative layer. The shield layer 204 in FIG. 2 as well as the shield layer 2604 of FIG. 26 is in the form of a tubular structure of braided conductive wires to provide a tubular braided shield layer. However, other forms of shield layers are also possible, for instance, a conductive foil tube. For a braided shield, the wires of the braid may be a conductor such as a biocompatible metal like tantalum, titanium, and the like. For a foil shield, the foil may be a conductor such as a biocompatible metal like titanium, tantalum, stainless steel, MP35N® alloy of SPS Technologies, Inc. of Jenkintown, Pa., and the like.


Where the shield layer 204 is a braided wire shield as shown in FIG. 2, the braid may be created with a variety of shield parameters. Examples of shield parameters such as braid angle, wire cross-sectional shape and diameter, number of braid wires, braid depth, distance from shield termination to closest contact or electrode, and the like that may also be used for the embodiments being disclosed herein are described in U.S. patent application Ser. No. 13/264,067, which is incorporated herein by reference in its entirety.


The shielded sheath 202 may be installed during a new implantation of the lead 104 or as a retrofit to a lead 104 that has previously been implanted. Examples of procedures for installing the shielded sheath 202 are discussed below, with the procedure for installing during a new spinal implantation of the lead 104 being described with reference to FIGS. 3-11 and the procedure for retrofitting a spinal lead 104 that has previously been implanted with reference to FIGS. 12-17. An example of a procedure for installing the shielded sheath for a brain lead is discussed below in relation to FIGS. 18-23.


In FIG. 11, the procedure for a new implantation of a lead 104 begins at an operation 1102 where a needle 304 as shown in FIG. 3 is being inserted through the spinal structures 308 and into the epidural space between the spinal structures 308 and the spinal cord 306. A guide wire 302 is then advanced through the needle 304 and into the epidural space at an operation 1104.


At an operation 1106, the needle 304 is then retracted while the guidewire 302 remains in the epidural space. This is shown in FIG. 4 where it can be seen that the guidewire 302 has maintained a position within the epidural space as the needle 304 has exited the epidural space.


At an operation 1108, the shielded sheath 202 having the shield layer 204 is advanced over the guidewire 302 and approaches the epidural space through the spinal structures 308. This is shown in FIG. 5. In this example, the shielded sheath 202 includes a tapered leading edge 206 which allows the shielded sheath 202 to more easily penetrate through the body tissues to reach the epidural space.


At an operation 1110, the guidewire 302 is retracted from the epidural space through the shielded sheath 202 while the shielded sheath 202 remains in the epidural space. This is shown in FIG. 6 where it can be seen that the shielded sheath 202 has maintained a position within the epidural space as the guidewire 302 has exited the epidural space.


At an operation 1112, an anchor 702 as shown in FIG. 7 is applied to the shielded sheath 202 to fasten the shield to the surrounding fascia at the spinal structures 308. In the example shown in FIG. 7, the anchor 702 is of the type that forms a sleeve that is then affixed to surrounding tissue via sutures 704. However, other types of anchoring may also be used. For instance, the shielded sheath 202 may be directly sutured.


At an operation 1114, the distal end of the lead 104 is inserted into the lumen of the shielded sheath 202 and is advanced toward the epidural space. This is shown in FIG. 8.


At an operation 1116, the lead 104 is advanced through the shielded sheath 202 to the stimulation site. As shown in FIG. 9, the distal end 105 of the lead 104 exits from the shielded sheath to then reach the stimulation site within the epidural space with the electrodes 106 being exposed to the spinal cord 306.


At an operation 1118, an anchor 1002 as shown in FIG. 10 is applied to the shielded sheath 202 to further fasten the shield to the surrounding fascia at the spinal structures 308 while also anchoring the lead to the shielded sheath. This, in turn, anchors the lead to the surrounding fascia. In the example shown in FIG. 10, the anchor 1002 is also of the type that forms a sleeve that is then affixed to surrounding tissue via sutures 1004. In the example shown in FIG. 10, another anchor 1003 is also installed at the point where the lead 104 exits the proximal end of the shielded sheath and affixed to surrounding tissue via sutures 1005. By overlapping the point where the lead 104 exits the shielded sheath, this anchor 1003 is partially directly engaging the lead 104 and partially directly engaging the shielded sheath to further anchor the lead 104 and shielded sheath together and to the tissue. However, other types of anchoring may also be used for the purpose of anchoring the lead to the shielded sheath. For instance, the shielded sheath may be provided with elasticity of the insulative body and a slightly smaller lumen diameter than the lead 104 near the ends such that the compression of the shielded sheath may anchor the sheath to the lead 104. Other examples of anchoring include utilizing an anchor that is elastic and provides compression to force the sheath tightly against the lead.


At an operation 1120, the proximal end 107 of the lead 104 having proximal contacts 109 and the shielded sheath 202 are tunneled together to the pocket 114 where the implantable medical device 102 is or will be positioned. This is also shown in FIG. 10.


At an operation 1122, the proximal end 107 of the lead 104 is connected to the implantable medical device 102 at the pocket 114. The proximal contacts 109 of the lead 104 establish electrical connections with corresponding electrical connectors of the implantable medical device 102 to complete the stimulation pathway to the electrodes 106 that are positioned at the stimulation site within the epidural space.


In FIG. 17, the procedure for a previously implanted lead 104 begins at an operation 1702 where the proximal end of the lead 107 is unplugged from the implantable medical device 102. A spinal incision is then opened nearby the entry site to the epidural space at an operation 1704.


At an operation 1706, an anchor 1204 as shown in FIG. 12 is being removed from the lead 104. Then, at an operation 1708, the lead 104 is pulled at the incision site to bring the proximal end 107 of the lead 104 to the incision cite. This is also shown in FIG. 12. It can further be seen in FIG. 12 that the distal end of the lead 104 is present within a scar capsule 1202 that has naturally formed about the distal end of the lead 104.


At an operation 1710, a shielded sheath 1302 is positioned over the lead 104 with the proximal end 107 of the lead 104 entering the lumen of the shielded sheath 202. This is shown in FIG. 13. The shielded sheath 1302 may be the same or different construction as the shielded sheath 202 and includes a shield layer 1304 that may be the same or different construction as the shield layer 204.


At an operation 1712, the shielded sheath 1302 is forced within the scar capsule 1202. A tapered leading edge 1306 may be included on the shielded sheath 1302 to assist in penetrating into the scar capsule 1202. This is shown in FIG. 14. The shielded sheath is advanced through the scar capsule until reaching a desired position proximal of the electrodes 106 on the distal end 105 of the lead 104 as shown in FIG. 15.


At an operation 1714, an anchor 1402 as also shown in FIG. 15 is applied to the shielded sheath 1302 to fasten the shielded sheath 1302 to the surrounding fascia at the spinal structures 308 while also anchoring the lead 104 to the shielded sheath 1302. This, in turn, anchors the lead 104 to the surrounding fascia. In the example shown in FIG. 15, the anchor 1402 is also of the type that forms a sleeve that is then affixed to surrounding tissue via sutures 1404. However, other types of anchoring may also be used for the purpose of anchoring the lead to the shielded sheath. For instance, the shielded sheath may be provided with elasticity of the insulative body and a slightly smaller lumen diameter than the lead 104 near the ends such that the compression of the shielded sheath may anchor the sheath to the lead 104. Other examples of anchoring include utilizing an anchor that is elastic and provides compression to force the sheath tightly against the lead.


At an operation 1716, the proximal end 107 of the lead 104 having proximal contacts 109 and the shielded sheath 1302 are tunneled together to the pocket 114 where the implantable medical device 102 is or will be positioned. This is shown in FIG. 16.


At an operation 1718, the proximal end 107 of the lead 104 is connected to the implantable medical device 102 at the pocket 114. The proximal contacts 109 of the lead 104 establish electrical connections with corresponding electrical connectors of the implantable medical device 102 to complete the stimulation pathway to the electrodes 106 that are positioned at the stimulation site within the epidural space.



FIG. 18 shows an implantable medical system 1814 which includes an implantable medical device 1802, an implantable medical lead 1804, and a lead extension that is connected between the lead 1804 and the implantable medical device 1802. The implantable medical device 1802 is positioned within a pocket 1819 formed in the upper torso and the lead extension extends through a subcutaneous tunnel 1820 formed when implanting the extension. The proximal end 1805 of the lead 1804 passes through the cranium via a hole 1818 to reach a stimulation site within the brain 1816 of the patient 1812.


The system 1814 also includes a first shielded sheath 1808 that has been placed over the lead 1804 and a second shielded sheath 1810 that has been placed over the lead extension. The shielded sheath 1808 is positioned between the proximal end where the lead 1804 connects to the extension and the distal end 1805 where the electrodes 1806 are located. The shielded sheath 1810 is positioned between the proximal end where the extension connects to the implantable medical device and the distal end where a connector housing is located. The shielded sheaths may be constructed like the examples discussed above for shielded sheath 202 and 2600. A cranial anchor may be installed onto the lead 1804 at the hole 1818 and the sheath 1808 naturally maintains its position between the hole 1818 and the distal connector 2102 of the extension 2104. Likewise, the second sheath 1810 naturally maintains its position between the distal end of the distal connector 2102 and the proximal end of the extension 2104. However, if desired, anchoring may be provided on the sheath 1808 and second sheath 1810 in this instance as well in the same manners as discussed above with respect to the spinal implantations.


In FIG. 23, the procedure for implanting the lead 1804, extension, and shielded sheaths 1808, 1810 begins at an operation 2302 where the lead 1804 as shown in FIG. 19 is being inserted through the hole 1818 of the cranium and into the brain 1816. The lead 1804 may be routed subcutaneously from an area behind the ear of the patient up to the hole 1818. The lead 104 may be anchored nearby the hole 1818.


In an operation 2304, the first shielded sheath 1808 is advanced over the lead 104. The proximal end of the lead 104 is inserted into the lumen of the shielded sheath 1808 and the shielded sheath 1808 is advanced toward the hole 1818. This is shown in FIG. 20. It can be seen that the shielded sheath 1808 has a tapered leading edge 1803 that assists in passing subcutaneously toward the hole 1818. It can also be seen that the shielded sheath 1808 has a shield layer 1807.


In an operation 2306, the proximal end of the lead 1804 is connected to the distal end connector 2102 on a distal end 2106 of the lead extension 2104 as shown in FIG. 21. This occurs via an incision site that has been created when initially tunneling the lead to the hole 1818. As also shown in FIG. 21, the second shielded sheath 1810 having a shield layer 1811 is advanced over the lead extension 2104 at an operation 2308.


In an operation 2308, the proximal end 2108 of the extension 2104 having proximal contacts 2110 and the second shielded sheath 1810 are tunneled together to the pocket 1819 where the implantable medical device 1802 is or will be positioned. This is shown in FIG. 22.


At an operation 2312, the proximal end 2108 of the extension 2104 is connected to the implantable medical device 1802 at the pocket 1819. The proximal contacts 2110 of the extension 2104 establish electrical connections with corresponding electrical connectors of the implantable medical device 1802 to complete the stimulation pathway to the electrodes 1806 that are positioned at the stimulation site within the brain 1816.



FIG. 24 shows an example of a shielded sheath 2402 that may be placed over a lead or an extension where the proximal end of the shielded sheath 2402 provides connectivity. In this example, a proximal contact 2406 such as a metal ring is positioned on the proximal end. This proximal contact 2406 may be in physical contact with the shield layer of the shielded sheath 2402 to provide an electrical connection from the shield layer to the proximal contact 2406. An implantable medical device 2404 may receive the proximal end of the shielded sheath 2402 into a bore where the lead or lead extension may also be inserted.


The implantable medical device 2404 may include an electrical connector such as a set screw 2410 and a corresponding set screw bore 2408 that allows a physical connection to be made with the proximal contact. This electrical connector 2410 then provides an electrical pathway to a grounding surface at the implantable medical device such as a metal housing. This effectively provides a tissue ground at the implantable medical device 2404 for the shield layer of the shielded sheath 2402 such that RF energy coupled to the shield may be diverted to the grounding surface and surrounding tissue of the implantable medical device 2404.



FIG. 25 shows an example of a shielded sheath 2502 that may be placed over a lead or an extension where the proximal end of the shielded sheath 2502 also provides connectivity. In this example, a proximal contact 2506 such as a metal ring is positioned on the proximal end. This proximal contact 2506 may be in physical contact with the shield layer of the shielded sheath 2502 to provide an electrical connection from the shield layer to the proximal contact 2506. The proximal contact 2506 also includes a smaller diameter region 2507. An implantable medical device 2404 may receive the proximal end of the shielded sheath 2402 and specifically the smaller diameter region 2507 of the proximal contact 2506 into a bore where the lead or lead extension may also be inserted. This bore may have a diameter that is smaller than the larger diameter region of the proximal contact 2506 but large enough to accept the smaller diameter region 2507.


The implantable medical device 2504 may include an electrical connector such as a set screw 2510 and a corresponding set screw bore 2508 that allows a physical connection to be made with the proximal contact region 2507. This electrical connector 2510 then provides an electrical pathway to a grounding surface at the implantable medical device such as a metal housing. This example also effectively provides a tissue ground at the implantable medical device 2504 for the shield layer of the shielded sheath 2502 such that RF energy coupled to the shield may be diverted to the grounding surface and surrounding tissue of the implantable medical device 2504.



FIG. 27 shows an implantable medical system 2700 that is implanted into the patient 108 and is similar to the implantable medical system of FIG. 2 except that the implantable medical system 2700 includes an implantable medical paddle lead 2802. The paddle lead 2802 has been implanted via an entry point 2704, typically created through a surgical procedure to create adequate space for the paddle portion 2806, and extends into the epidural space of the spine 110. The paddle lead 2802 includes a paddle portion 2804 that includes an array of electrodes 2806. The paddle lead 2802 is connected to an implantable medical stimulation device 2702 that is located in a pocket 114. A shielded sheath 2812 of the same construction as the prior embodiments discussed herein is positioned over the lead body of the paddle lead 2802.


As can be seen in FIG. 27 as well as in FIG. 28, the inside diameter of the shielded sheath 2812 is large enough to fit over the lead body. However, the width of the paddle portion 2804 is larger than the inside diameter of the shielded sheath 2812, which confines the position of the shielded sheath 2812 on the lead 2802. FIG. 28 further shows that the paddle lead 2802 and the shielded sheath 2812 are positioned within the epidural space by passing through the spinal structures 308 which may be further manipulated surgically when introducing the paddle portion 2804. Where the shielded sheath 2812 is being installed at the time of implantation of the lead 2802, various procedures are possible as discussed with reference to FIGS. 29 and 30. Where the lead 2802 is already implanted, then the shielded sheath 2812 may be added such as by a procedure shown in FIG. 31.


The procedure of FIG. 29 begins by the paddle lead 2802 being implanted into the epidural space to place the paddle portion 2804 at the target site at operation 2902. The shielded sheath 2812 is then positioned over the paddle lead 2802 by feeding the proximal end of the paddle lead 2802 into the distal end of the shielded sheath and advancing the shielded sheath 2812 into the epidural space toward the paddle portion 2804 while the position of the lead 2802 is maintained at an operation 2904. Once the shielded sheath 2812 has been fully advanced onto the lead 2802, it may be desirable in some instances to also create a strain relief loop in the combination of the paddle lead 2802 and attached sheath 2812, such that the strain relief loop is shielded, at this intermediate location in the body of the patient near the entry to the epidural space. The proximal end of the lead 2802 and the shielded sheath 2812 positioned on the lead 2802 are then tunneled to the pocket 114 at an operation 2906. The proximal end 2808 of the lead 2802, which includes contacts 2810, is then connected to the stimulation device 2702 at an operation 2908. It may also be desirable in some instances to create a strain relief loop in the combination of the paddle lead 2802 and attached sheath 2812, such that the strain relief loop is shielded, at this location near the pocket 114 prior to connecting the proximal end 2808 to the device 2702.


An alternative procedure as shown in FIG. 30 begins by the shielded sheath 2812 being positioned over the paddle lead 2802. The proximal end of the paddle lead 2802 is fed into the distal end of the shielded sheath, and the shielded sheath 2812 is advanced toward the paddle portion 2804 prior to implantation of the lead 2802 at an operation 3002. The paddle lead 2802 and shielded sheath 218 are then implanted into the epidural space to place the paddle portion 2804 at the target site at operation 2902 at an operation 3004. With the shielded sheath 2812 fully advanced onto the lead 2802 and the combination of the shielded sheath 2812 and lead 2802 having been fully advanced to the stimulation site within the epidural space, it may be desirable in some instances to also create a strain relief loop in the combination of the paddle lead 2802 and attached sheath 2812, such that the strain relief loop is shielded, at this intermediate location in the body of the patient near the entry to the epidural space. The proximal end of the lead 2802 and the shielded sheath 2812 positioned on the lead 2802 are then tunneled to the pocket 114 at an operation 3006. The proximal end 2808 of the lead 2802, which includes contacts 2810, is then connected to the stimulation device 2702 at an operation 3008. It may also be desirable in some instances to create a strain relief loop in the combination of the paddle lead 2802 and attached sheath 2812, such that the strain relief loop is shielded, at this location near the pocket 114 prior to connecting the proximal end 2808 to the device 2702.


The procedures of FIG. 31A or 31B may be used to retrofit an implanted paddle lead 2802 with a shielded sheath 2812. The example of FIG. 31A may be implemented when a strain relief loop is either not already present or is present but not fibrosed and a strain relief loop is not desired upon placing the shielded sheath 2812 onto the lead 2802. This procedure begins by unplugging the proximal end 2808 of the lead 2802 from the stimulation device 2702 at an operation 3101. If there is a strain relief loop that is present but not fibrosed, then the lead may be gently pulled in the proximal direction to straighten the existing strain relief loop. The shielded sheath 2812 is then positioned over the paddle lead 2802 by feeding the exposed proximal end of the paddle lead 2802 into the distal end of the shielded sheath 2812 and advancing the shielded sheath 2812 into the epidural space toward the paddle portion 2804 while the position of the lead 2802 is maintained at an operation 3103. The shielded sheath 2812 may be forced into a scar capsule that has formed around the distal area of the lead present in the epidural space in order to fully advance the shielded sheath 2812 to the paddle portion 2804 at an operation 3105. The proximal end 2808 of the lead 2802, which includes contacts 2810, is then connected to the stimulation device 2702 at an operation 3107.


The example of FIG. 31B may be implemented when one or more strain relief loops are already present and fibrosed and/or are desired upon placing the shielded sheath 2812 onto the lead 2802. This procedure begins by unplugging the proximal end 2808 of the lead 2802 from the stimulation device 2702 at an operation 3102. The point of entry 2704, typically a surgical incision, of the lead 2802 into the epidural space may be reopened to access the lead 2802 at an operation 3104. The lead 2802 is then pulled from the pocket 114 to the point of entry 2704 to pull any existing strain relief loop straight and to gain access to the proximal end of the lead 2802 at an operation 3106. The shielded sheath 2812 is then positioned over the paddle lead 2802 by feeding the exposed proximal end of the paddle lead 2802 into the distal end of the shielded sheath and advancing the shielded sheath 2812 into the epidural space toward the paddle portion 2804 while the position of the lead 2802 is maintained at an operation 3108. The shielded sheath 2812 may be forced into a scar capsule that has formed around the distal area of the lead present in the epidural space in order to fully advance the shielded sheath 2812 to the paddle portion 2804 at an operation 3110. With the shielded sheath 2812 fully advanced onto the lead 2802, it may be desirable in some instances to also create a strain relief loop in the combination of the paddle lead 2802 and attached sheath 2812, such that the strain relief loop is shielded, at this intermediate location in the body of the patient near the entry to the epidural space. The proximal end of the lead 2802 and the shielded sheath 2812 positioned on the lead 2802 are then tunneled to the pocket 114 at an operation 3112. The proximal end 2808 of the lead 2802, which includes contacts 2810, is then connected to the stimulation device 2702 at an operation 3114. It may also be desirable in some instances to create a strain relief loop in the combination of the paddle lead 2802 and attached sheath 2812, such that the strain relief loop is shielded, at this location near the pocket 114 prior to connecting the proximal end 2808 to the device 2702.


Should the paddle lead 2802 require an extension to reach the target site, FIG. 32 shows an example of such a configuration. Here, the proximal end 2810 of the lead 2802 has been connected to a distal connector block 3208 of connectors of a lead extension 3202. The shielded sheath 2812 is present on the lead 2802 while a second shielded sheath 3204 is present on the lead extension 3202. The second shielded sheath 3204 includes a portion 3206 that covers the distal connector block 3208 of the extension 3202. The proximal end of the lead 2802 includes contacts 3210 that are plugged into the stimulation device 2702.


The shielded sheath 2812 of FIGS. 27, 28, and 32 as well as the second shielded sheath 3204 may also include an electrical contact, such as the contact 2406 in FIG. 24, on the proximal end that can then establish a ground path with the stimulation device 2702. As another example, the electrical contact of the shielded sheath 2812 or second shielded sheath 3204 may have a first portion with a first diameter and a second portion and a second diameter that is smaller than the first, as shown in FIG. 25.


While embodiments have been particularly shown and described, it will be understood by those skilled in the art that various other changes in the form and details may be made therein without departing from the spirit and scope of the invention.

Claims
  • 1. An apparatus comprising: an implantable medical lead having a most distal proximal contact and a most proximal distal electrode;a sheath containing a shield layer positioned about the implantable medical lead between the most distal proximal contact and the most proximal distal electrode, the sheath having an outer diameter greater than an outer diameter of the proximal contact and the distal electrode, the sheath also having a proximal end positioned distally of the most distal proximal contact and having a distal end positioned proximally of the most proximal distal electrode; andan anchoring structure holding the sheath in a fixed position about the implantable medical lead, the anchoring structure comprising a sleeve positioned around an exterior circumference of the sheath so as to overlap a point where the lead exits the sheath to partially directly engage the lead and partially directly engage the sheath and a suture wrapped around an exterior circumference of the sleeve.
  • 2. The apparatus of claim 1, wherein the shield layer comprises braided wires.
  • 3. The apparatus of claim 1, wherein the shield layer is encapsulated within a polymer of the sheath.
  • 4. The apparatus of claim 1, further comprising an electrical contact on the proximal end of the sheath in electrical contact with the shield layer.
  • 5. The apparatus of claim 4, wherein the electrical contact has a first portion with a first diameter and a second portion with a second diameter that is smaller than the first diameter.
  • 6. An implantable medical system, comprising: an implantable stimulation device;an implantable medical lead having a most distal proximal contact and a most proximal distal electrode with the most distal proximal contact being electrically coupled to the implantable stimulation device;a sheath containing a shield layer positioned about the implantable medical lead between the proximal contact and the distal electrode, the sheath having an outer diameter greater than an outer diameter of the proximal contact and the distal electrode, the sheath also having a proximal end positioned distally of the most distal proximal contact and having a distal end positioned proximally of the most proximal distal electrode; andan anchoring structure holding the sheath in a fixed position about the implantable medical lead, the anchoring structure comprising a sleeve positioned around an exterior circumference of the sheath so as to overlap a point where the lead exits the sheath to partially directly engage the lead and partially directly engage the sheath and a suture wrapped around an exterior circumference of the sleeve.
  • 7. The system of claim 6, wherein the shield layer comprises braided wires.
  • 8. The system of claim 6, wherein the shield layer is encapsulated within a polymer of the sheath.
  • 9. The system of claim 6, wherein the implantable medical lead is physically coupled directly to the implantable stimulation device.
  • 10. The system of claim 6, further comprising: an implantable medical lead extension having a proximal contact and a distal connector block, a second sheath containing a shield layer positioned about the implantable medical lead extension between the proximal contact and a distal end of the implantable medical lead extension, wherein the proximal contact of the implantable medical lead is directly coupled to the distal connector block and wherein the proximal contact of the implantable medical lead extension is directly coupled to the implantable stimulation device; andan anchoring structure holding the second sheath in a fixed position about the implantable medical lead extension.
  • 11. The system of claim 6, wherein at least one end of the sheath includes a tapered edge.
  • 12. The apparatus of claim 1, wherein at least one end of the sheath includes a tapered edge.
RELATED APPLICATIONS

The present application claims priority to U.S. Provisional Application No. 62/028,798, filed Jul. 24, 2014, which is incorporated herein in its entirety.

US Referenced Citations (476)
Number Name Date Kind
2433480 Rendich Dec 1947 A
2487038 Jasper Nov 1949 A
3788329 Friedman Jan 1974 A
3842485 Bemert Oct 1974 A
3915174 Preston Oct 1975 A
4033355 Amundson Jul 1977 A
4038990 Thompson Aug 1977 A
4214804 Little Jul 1980 A
4220813 Kyle Sep 1980 A
4280507 Rosenberg Jul 1981 A
4320763 Money Mar 1982 A
4350169 Dutcher Sep 1982 A
4383225 Mayer May 1983 A
4403824 Scott Sep 1983 A
4411276 Dickhudt Oct 1983 A
4441498 Nordling Apr 1984 A
4628942 Sweeney et al. Dec 1986 A
4683895 Pohndorf Aug 1987 A
4711027 Harris Dec 1987 A
4726379 Altman et al. Feb 1988 A
4852585 Heath Aug 1989 A
4906241 Noddin Mar 1990 A
4920980 Jackowski May 1990 A
4922607 Doan et al. May 1990 A
4934380 De Toledo Jun 1990 A
4947866 Lessar et al. Aug 1990 A
4951672 Buchwald et al. Aug 1990 A
4991583 Silvian Feb 1991 A
5003992 Holleman Apr 1991 A
5005587 Scott Apr 1991 A
5012045 Sato Apr 1991 A
5018523 Bach, Jr. et al. May 1991 A
5020544 Dahl et al. Jun 1991 A
5020545 Soukup Jun 1991 A
5036862 Pohndorf Aug 1991 A
5040544 Lessar et al. Aug 1991 A
5063932 Dahl et al. Nov 1991 A
5197468 Proctor et al. Mar 1993 A
5213111 Cook et al. May 1993 A
5217010 Tsitlik et al. Jun 1993 A
5231078 Riebman et al. Jul 1993 A
5243996 Hall Sep 1993 A
5246438 Langberg Sep 1993 A
5260128 Ishii et al. Nov 1993 A
5265608 Lee et al. Nov 1993 A
5265623 Kroll et al. Nov 1993 A
5271417 Swanson et al. Dec 1993 A
5308664 House et al. May 1994 A
5314459 Swanson et al. May 1994 A
5323776 Blakely et al. Jun 1994 A
5335657 Terry, Jr. et al. Aug 1994 A
5349133 Rogers Sep 1994 A
5360441 Otten Nov 1994 A
5366496 Dahl et al. Nov 1994 A
5370644 Langberg Dec 1994 A
5374286 Morris Dec 1994 A
5374778 Hashimoto et al. Dec 1994 A
5417719 Hull et al. May 1995 A
5456705 Morris Oct 1995 A
5458629 Baudino et al. Oct 1995 A
5458631 Xavier Oct 1995 A
5466252 Soukup et al. Nov 1995 A
5473812 Morris et al. Dec 1995 A
5476496 Strandberg et al. Dec 1995 A
5485667 Kleshinski Jan 1996 A
5500013 Buscemi et al. Mar 1996 A
5504274 McCabe et al. Apr 1996 A
5514172 Mueller May 1996 A
5515848 Corbett, III et al. May 1996 A
5523534 Meister et al. Jun 1996 A
5523578 Herskovic Jun 1996 A
5527348 Winkler Jun 1996 A
5534018 Wahlstrand Jul 1996 A
5552565 Cartier et al. Sep 1996 A
5571157 McConnell Nov 1996 A
5572594 DeVoe et al. Nov 1996 A
5591218 Jacobson Jan 1997 A
5594304 Graber Jan 1997 A
5606981 Tartacower et al. Mar 1997 A
5609622 Soukup et al. Mar 1997 A
5628780 Helland et al. May 1997 A
5629622 Scampini May 1997 A
5643254 Scheldrup et al. Jul 1997 A
5649965 Pons et al. Jul 1997 A
5662697 Li et al. Sep 1997 A
5676659 McGurk Oct 1997 A
5676694 Boser et al. Oct 1997 A
5683435 Truex et al. Nov 1997 A
5683444 Huntley et al. Nov 1997 A
5697909 Eggers et al. Dec 1997 A
5697958 Paul et al. Dec 1997 A
5702437 Baudino Dec 1997 A
5706826 Schwager Jan 1998 A
5722998 Prutchi et al. Mar 1998 A
5727552 Ryan Mar 1998 A
5751539 Stevenson et al. May 1998 A
5766232 Grevious et al. Jun 1998 A
5782241 Felblinger et al. Jul 1998 A
5795341 Samson Aug 1998 A
5807258 Cimochowski et al. Sep 1998 A
5814076 Brownlee Sep 1998 A
5827997 Chung et al. Oct 1998 A
5830136 Delonzor et al. Nov 1998 A
5842966 Markoll Dec 1998 A
5842986 Avrin et al. Dec 1998 A
5851226 Skubitz et al. Dec 1998 A
5897584 Herman Apr 1999 A
5905627 Brendel et al. May 1999 A
5927345 Samson Jul 1999 A
5931861 Werner et al. Aug 1999 A
5954760 Jarl Sep 1999 A
5964705 Truwit et al. Oct 1999 A
5968087 Hess Oct 1999 A
5970429 Martin Oct 1999 A
5942966 Markoll Dec 1999 A
6004269 Crowley Dec 1999 A
6016447 Juran et al. Jan 2000 A
6024703 Zanelli et al. Feb 2000 A
6032063 Hoar et al. Feb 2000 A
6033408 Gage et al. Mar 2000 A
6055457 Bonner Apr 2000 A
6101417 Vogel et al. Aug 2000 A
6103037 Wilson Aug 2000 A
6108582 Fischer, Sr. Aug 2000 A
6132390 Cookston et al. Oct 2000 A
6141593 Patag Oct 2000 A
6143013 Samson et al. Nov 2000 A
6152746 Brown Nov 2000 A
6156029 Mueller Dec 2000 A
6195267 MacDonald et al. Feb 2001 B1
6198807 DeSena Mar 2001 B1
6198972 Hartlaub et al. Mar 2001 B1
6209764 Hartlaub et al. Apr 2001 B1
6240322 Peterfeso May 2001 B1
6258071 Brookes Jul 2001 B1
6265466 Glatkowski Jul 2001 B1
6269148 Jessop et al. Jul 2001 B1
6284971 Atalar et al. Sep 2001 B1
6302740 Holmstrom Oct 2001 B1
6348070 Teissl et al. Feb 2002 B1
6424234 Stevenson Jul 2002 B1
6471699 Fleischman et al. Oct 2002 B1
6488704 Connelly et al. Dec 2002 B1
6494916 Babalola et al. Dec 2002 B1
6501991 Honeck et al. Dec 2002 B1
6503648 Wang Jan 2003 B1
6506972 Wang Jan 2003 B1
6529774 Greene Mar 2003 B1
6538191 MacDonald Mar 2003 B1
6583361 Clouet Jun 2003 B2
6606521 Paspa et al. Aug 2003 B2
6640137 MacDonald Oct 2003 B2
6648690 Saito et al. Nov 2003 B2
6660116 Wolf et al. Dec 2003 B2
6671544 Baudino Dec 2003 B2
6671554 Gibson et al. Dec 2003 B2
6673999 Wang et al. Jan 2004 B1
6675033 Lardo et al. Jan 2004 B1
6689835 Amarasekera et al. Feb 2004 B2
6695761 Oschman et al. Feb 2004 B2
6708051 Durousseau Mar 2004 B1
6711440 Deal et al. Mar 2004 B2
6712844 Pacetti et al. Mar 2004 B2
6713671 Wang et al. Mar 2004 B1
6718203 Weiner et al. Apr 2004 B2
6718207 Connelly Apr 2004 B2
6725092 MacDonald et al. Apr 2004 B2
6735471 Hill et al. May 2004 B2
6741892 Meadows et al. May 2004 B1
6743055 Flynn Jun 2004 B1
6750055 Connelly et al. Jun 2004 B1
6757566 Weiner et al. Jun 2004 B2
6760628 Weiner et al. Jul 2004 B2
6763268 MacDonald et al. Jul 2004 B2
6765144 Wang et al. Jul 2004 B1
6768053 Wang et al. Jul 2004 B1
6778856 Connelly et al. Aug 2004 B2
6792316 Sass Sep 2004 B2
6793642 Connelly et al. Sep 2004 B2
6795730 Connelly et al. Sep 2004 B2
6795736 Connelly et al. Sep 2004 B2
6799067 Pacetti Sep 2004 B2
6799069 Weiner et al. Sep 2004 B2
6815609 Wang et al. Nov 2004 B1
6819954 Connelly Nov 2004 B2
6819958 Weiner et al. Nov 2004 B2
6844492 Wang et al. Jan 2005 B1
6845259 Pacetti et al. Jan 2005 B2
6845267 Harrison et al. Jan 2005 B2
6846985 Wang et al. Jan 2005 B2
6850805 Connelly et al. Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6863653 Zanelli et al. Mar 2005 B1
6864418 Wang et al. Mar 2005 B2
6869683 Sakurai et al. Mar 2005 B2
6871091 Wilkinson et al. Mar 2005 B2
6872882 Fritz Mar 2005 B2
6875180 Weiner et al. Apr 2005 B2
6879861 Benz et al. Apr 2005 B2
6882519 Uzawa et al. Apr 2005 B2
6895280 Meadows et al. May 2005 B2
6901287 Davis et al. May 2005 B2
6901290 Foster et al. May 2005 B2
6906256 Wang Jun 2005 B1
6920361 Williams Jul 2005 B2
6922590 Whitehurst Jul 2005 B1
6925328 Foster et al. Aug 2005 B2
6930242 Helfer Aug 2005 B1
6937906 Terry et al. Aug 2005 B2
6944489 Zeiljemaker et al. Sep 2005 B2
6949929 Gray et al. Sep 2005 B2
6954674 Connelly Oct 2005 B2
6968235 Belden et al. Nov 2005 B2
6968236 Hagele Nov 2005 B2
6971391 Wang et al. Dec 2005 B1
6980865 Wang et al. Dec 2005 B1
6982378 Dickson Jan 2006 B2
6985775 Reinke et al. Jan 2006 B2
6993387 Connelly et al. Jan 2006 B2
6999818 Stevenson et al. Feb 2006 B2
6999821 Jenney et al. Feb 2006 B2
7001369 Griffin et al. Feb 2006 B2
7013174 Connelly et al. Mar 2006 B2
7013180 Villaseca et al. Mar 2006 B2
7015392 Dickenson Mar 2006 B1
7015393 Weiner Mar 2006 B2
7047084 Erickson May 2006 B2
7050855 Zeijlemaker et al. May 2006 B2
7058192 Muller et al. Jun 2006 B2
7076283 Cho et al. Jul 2006 B2
7076302 Scheiner Jul 2006 B2
7082328 Funke Jul 2006 B2
7082337 Sommer et al. Jul 2006 B2
7103413 Swanson Sep 2006 B2
7113827 Silvestri Sep 2006 B2
7115134 Chambers Oct 2006 B2
7118693 Glatkowski et al. Oct 2006 B2
7123013 Gray Oct 2006 B2
7125409 Truckai et al. Oct 2006 B2
7162302 Wang et al. Jan 2007 B2
7174219 Wahlstrand et al. Feb 2007 B2
7187980 Osypka et al. Mar 2007 B2
7233825 Jorgenson et al. Jun 2007 B2
7257449 Bodner Aug 2007 B2
7282260 LeGrande et al. Oct 2007 B2
7286871 Cohen Oct 2007 B2
7286882 Cole Oct 2007 B2
7292894 Belden Nov 2007 B2
7294785 Uutela et al. Nov 2007 B2
7319901 Dublin Jan 2008 B2
7363090 Halperin Apr 2008 B2
7389148 Morgan Jun 2008 B1
7540865 Griffin et al. Jun 2009 B2
7548788 Chinn et al. Jun 2009 B2
7591831 Parsonage et al. Sep 2009 B2
7674972 Gladd et al. Mar 2010 B2
7711436 Stone May 2010 B2
7729777 Gray et al. Jun 2010 B2
7738942 Weiner Jun 2010 B2
7813811 Wingeier et al. Oct 2010 B2
7819826 Diederich et al. Oct 2010 B2
7822484 Zhao et al. Oct 2010 B1
7828833 Haverkost Nov 2010 B2
7844343 Wahlstrand Nov 2010 B2
7844344 Wahlstrand Nov 2010 B2
7853332 Olsen Dec 2010 B2
7877150 Hoegh et al. Jan 2011 B2
7904178 Williams Mar 2011 B2
7917213 Bulkes Mar 2011 B2
7933652 Phillips Apr 2011 B2
8007440 Magnin et al. Aug 2011 B2
8027736 Wahlstrand Sep 2011 B2
8036756 Swoyer et al. Oct 2011 B2
8048060 Griffin et al. Nov 2011 B2
8055351 Atalar et al. Nov 2011 B2
8106657 Sakellariou et al. Jan 2012 B2
8170691 Eckerdal May 2012 B2
8202259 Evans et al. Jun 2012 B2
8246643 Nita Aug 2012 B2
8275464 Li et al. Sep 2012 B2
8280526 Wahlstrand Oct 2012 B2
8483842 Alexander et al. Jul 2013 B2
8543222 Sochor Sep 2013 B1
8620455 Alexander et al. Dec 2013 B2
8676340 Wahlstrand Mar 2014 B2
8744598 Alexander et al. Jun 2014 B2
8788061 Mehdizadeth Jul 2014 B2
8805534 Olsen Aug 2014 B2
8903504 Hegland Dec 2014 B2
9002474 Olsen Apr 2015 B2
9037263 Marshall May 2015 B2
9044593 Li Jun 2015 B2
20010044646 Marshall et al. Nov 2001 A1
20020032468 Hill Mar 2002 A1
20020038135 Connelly et al. Mar 2002 A1
20020058978 Sass May 2002 A1
20020183438 Amarasekera et al. May 2002 A1
20020082673 Benz et al. Jun 2002 A1
20020106918 Saito et al. Aug 2002 A1
20020111659 Davis et al. Aug 2002 A1
20020111663 Dahl et al. Aug 2002 A1
20020116028 Greatbatch et al. Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116033 Greatbatch et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020128689 Connelly et al. Sep 2002 A1
20020128691 Connelly Sep 2002 A1
20020133086 Connelly et al. Sep 2002 A1
20020133199 MacDonald et al. Sep 2002 A1
20020133200 Weiner et al. Sep 2002 A1
20020133201 Connelly et al. Sep 2002 A1
20020133202 Connelly et al. Sep 2002 A1
20020133208 Connelly Sep 2002 A1
20020133211 Weiner et al. Sep 2002 A1
20020133216 Connelly et al. Sep 2002 A1
20020138102 Weiner et al. Sep 2002 A1
20020138107 Weiner et al. Sep 2002 A1
20020138108 Weiner et al. Sep 2002 A1
20020138110 Connelly et al. Sep 2002 A1
20020138112 Connelly et al. Sep 2002 A1
20020143377 Wessman et al. Oct 2002 A1
20020183740 Edwards et al. Dec 2002 A1
20020183822 Bodner Dec 2002 A1
20020188345 Pacetti Dec 2002 A1
20030009207 Paspa et al. Jan 2003 A1
20030014080 Baudino Jan 2003 A1
20030036776 Foster et al. Feb 2003 A1
20030044623 Sakurai et al. Mar 2003 A1
20030045920 Belden et al. Mar 2003 A1
20030060732 Jacobsen et al. Mar 2003 A1
20030083570 Cho et al. May 2003 A1
20030083723 Wilkinson et al. May 2003 A1
20030083726 Zeijlemaker et al. May 2003 A1
20030093107 Parsonage et al. May 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030117787 Nakauchi Jun 2003 A1
20030120148 Pacetti Jun 2003 A1
20030120197 Kaneko et al. Jun 2003 A1
20030135114 Pacetti et al. Jul 2003 A1
20030139794 Jenney et al. Jul 2003 A1
20030139806 Haverkost et al. Jul 2003 A1
20030140931 Zeijlemaker Jul 2003 A1
20030144704 Terry Jul 2003 A1
20030144705 Funke Jul 2003 A1
20030144716 Reinke et al. Jul 2003 A1
20030144717 Hegele Jul 2003 A1
20030144718 Zeijlemaker Jul 2003 A1
20030144719 Zeijlemaker Jul 2003 A1
20030144720 Villaseca et al. Jul 2003 A1
20030144721 Villaseca et al. Jul 2003 A1
20030167052 Lee et al. Sep 2003 A1
20030204217 Greatbatch Oct 2003 A1
20030225331 Diederich et al. Dec 2003 A1
20040020674 McFadden et al. Feb 2004 A1
20040024442 Sowinski et al. Feb 2004 A1
20040028859 LeGrande et al. Feb 2004 A1
20040068307 Goble Apr 2004 A1
20040071949 Glatkowski et al. Apr 2004 A1
20040088012 Kroll et al. May 2004 A1
20040106958 Mathis et al. Jun 2004 A1
20040162600 Williams Aug 2004 A1
20040167443 Shireman et al. Aug 2004 A1
20040173368 Dickson Sep 2004 A1
20040199069 Connelly et al. Oct 2004 A1
20040220549 Dittman et al. Nov 2004 A1
20040249428 Wang et al. Dec 2004 A1
20040251042 Weiner et al. Dec 2004 A1
20040263172 Gray et al. Dec 2004 A1
20040263173 Gray Dec 2004 A1
20040263174 Gray et al. Dec 2004 A1
20040267328 Duffin Dec 2004 A1
20050065587 Gryzwa Mar 2005 A1
20050070972 Wahlstrand Mar 2005 A1
20050080471 Chitre et al. Apr 2005 A1
20050113876 Weiner May 2005 A1
20050115624 Walak Jun 2005 A1
20050137664 Sommer et al. Jun 2005 A1
20050145307 Shireman et al. Jul 2005 A1
20050159661 Connelly et al. Jul 2005 A1
20050182471 Wang Aug 2005 A1
20050222642 Przybyszewski Oct 2005 A1
20050222647 Wahlstrand Oct 2005 A1
20050222656 Wahlstrand Oct 2005 A1
20050222657 Wahlstrand Oct 2005 A1
20050222658 Hoegh et al. Oct 2005 A1
20050222659 Olsen Oct 2005 A1
20060030918 Chinn et al. Feb 2006 A1
20060036306 Heist et al. Feb 2006 A1
20060079926 Desai et al. Apr 2006 A1
20060089680 Bruchmann et al. Apr 2006 A1
20060095078 Tronnes May 2006 A1
20060135962 Kick et al. Jun 2006 A1
20060155270 Hancock Jul 2006 A1
20060167522 Malinowski Jul 2006 A1
20060167527 Malinowski Jul 2006 A1
20060200218 Wahlstrand Sep 2006 A1
20060224207 Dublin Oct 2006 A1
20060247747 Olsen Nov 2006 A1
20060247748 Wahlstrand Nov 2006 A1
20070021811 D'Aquanni et al. Jan 2007 A1
20070106332 Denker May 2007 A1
20070123805 Shireman et al. May 2007 A1
20070129779 Ayre Jun 2007 A1
20070168008 Olsen Jul 2007 A1
20070185556 Williams Aug 2007 A1
20070208383 Williams Sep 2007 A1
20070293924 Belden et al. Dec 2007 A1
20080033497 Bulkes Feb 2008 A1
20080039709 Karmarkar Feb 2008 A1
20080058715 Houser et al. Mar 2008 A1
20080154326 Clyne Jun 2008 A1
20080183263 Alexander Jul 2008 A1
20080195186 Li Aug 2008 A1
20080195187 Li Aug 2008 A1
20080215008 Nance et al. Sep 2008 A1
20080242944 Sharma Oct 2008 A1
20080243081 Nance et al. Oct 2008 A1
20080243218 Bottomley Oct 2008 A1
20080262582 Alexander Oct 2008 A1
20080262584 Bottomley Oct 2008 A1
20080269863 Alexander Oct 2008 A1
20080287804 Nita Nov 2008 A1
20090171421 Atalar et al. Jul 2009 A1
20090204192 Carlton Aug 2009 A1
20090221970 Spinoza Sep 2009 A1
20090228074 Edgell et al. Sep 2009 A1
20090234402 Marshall Sep 2009 A1
20090240235 Murata Sep 2009 A1
20090259272 Reddy Oct 2009 A1
20090270956 Vase Oct 2009 A1
20090287189 Suwito Nov 2009 A1
20100036466 Min Feb 2010 A1
20100069743 Sheetz et al. Mar 2010 A1
20100100164 Johnson et al. Apr 2010 A1
20100137957 Eckerdal Jun 2010 A1
20100145426 Stone Jun 2010 A1
20100198327 Helland Aug 2010 A1
20100256528 Lippert et al. Oct 2010 A1
20100256604 Lippert et al. Oct 2010 A1
20100256696 Schleicher et al. Oct 2010 A1
20100268310 Bonde et al. Oct 2010 A1
20100331938 Sommer Dec 2010 A1
20110015713 Min Jan 2011 A1
20110034983 Min Feb 2011 A1
20110071599 Olsen Mar 2011 A1
20110071604 Wahlstrand Mar 2011 A1
20110071605 Wahlstrand Mar 2011 A1
20110112615 Hoegh et al. May 2011 A1
20110230943 Johnson et al. Sep 2011 A1
20110251487 Magnin et al. Oct 2011 A1
20110319905 Palme et al. Dec 2011 A1
20120010689 Wahlstrand Jan 2012 A1
20120035616 Olsen et al. Feb 2012 A1
20120035694 Olsen Feb 2012 A1
20120035695 Olsen et al. Feb 2012 A1
20120035696 Kern Feb 2012 A1
20120035697 Stone Feb 2012 A1
20120035951 Goetz Feb 2012 A1
20120041528 Mehdizadeh et al. Feb 2012 A1
20120041529 Olsen Feb 2012 A1
20120046722 Olsen Feb 2012 A1
20120053664 Hegland Mar 2012 A1
20120059467 Drew Mar 2012 A1
20120130461 Olsen May 2012 A1
20120283835 Bentley Nov 2012 A1
20120330383 Wahlstrand Dec 2012 A1
20130296991 Alexander et al. Nov 2013 A1
20130317518 Govea Nov 2013 A1
20140107746 Alexander et al. Apr 2014 A1
20140200643 Wahlstrand Jul 2014 A1
20140288626 Alexander et al. Sep 2014 A1
20140345132 Mehdizadeh et al. Nov 2014 A1
20140350654 Olsen et al. Nov 2014 A1
20150082618 Hegland Mar 2015 A1
20150170792 Alford Jun 2015 A1
20150374977 Howard Dec 2015 A1
Foreign Referenced Citations (81)
Number Date Country
0617978 Oct 1994 EP
0624383 Nov 1994 EP
0713714 May 1996 EP
0760196 Mar 1997 EP
0920239 Jun 1999 EP
1273922 Jan 2003 EP
1424095 Jun 2004 EP
1466576 Oct 2004 EP
1625875 Feb 2006 EP
1632265 Mar 2006 EP
1935449 Jun 2008 EP
2429154 Feb 2007 GB
07255863 Oct 1995 JP
11086641 Mar 1999 JP
WO95032673 Dec 1995 WO
WO96016694 Jun 1996 WO
WO96028951 Sep 1996 WO
WO97041923 Nov 1997 WO
WO98048896 Nov 1998 WO
WO99010035 Mar 1999 WO
WO99019020 Apr 1999 WO
WO99060370 Nov 1999 WO
WO00027279 May 2000 WO
WO01080940 Nov 2001 WO
WO02000292 Jan 2002 WO
WO02083236 Oct 2002 WO
WO03037429 May 2003 WO
WO03061755 Jul 2003 WO
WO03063946 Aug 2003 WO
WO03063948 Aug 2003 WO
WO03063952 Aug 2003 WO
WO03063953 Aug 2003 WO
WO03063954 Aug 2003 WO
WO03063955 Aug 2003 WO
WO03063956 Aug 2003 WO
WO03063957 Aug 2003 WO
WO03075797 Sep 2003 WO
WO03092326 Nov 2003 WO
WO03095022 Nov 2003 WO
WO04012809 Feb 2004 WO
WO04052448 Jun 2004 WO
WO04073040 Aug 2004 WO
WO05030322 Apr 2005 WO
WO05032654 Apr 2005 WO
WO05102444 Nov 2005 WO
WO05102445 Nov 2005 WO
WO05102446 Nov 2005 WO
WO05102447 Nov 2005 WO
WO06031317 Mar 2006 WO
WO06093685 Sep 2006 WO
WO06093686 Sep 2006 WO
WO06118640 Nov 2006 WO
WO06118641 Nov 2006 WO
WO07047966 Apr 2007 WO
WO07124273 Nov 2007 WO
WO07126657 Nov 2007 WO
WO07149757 Dec 2007 WO
WO08100840 Feb 2008 WO
WO08088568 Jul 2008 WO
WO08100839 Aug 2008 WO
WO08111986 Sep 2008 WO
WO08130409 Oct 2008 WO
WO08134196 Nov 2008 WO
WO08140376 Nov 2008 WO
WO09011440 Sep 2009 WO
WO09134901 Nov 2009 WO
WO10062988 Jun 2010 WO
WO10126871 Nov 2010 WO
WO10126877 Nov 2010 WO
WO10126884 Nov 2010 WO
WO10126887 Nov 2010 WO
WO10126935 Nov 2010 WO
WO10126939 Nov 2010 WO
WO10126943 Nov 2010 WO
WO10126946 Nov 2010 WO
WO10126949 Nov 2010 WO
WO10126975 Nov 2010 WO
WO10135440 Nov 2010 WO
WO11019416 Feb 2011 WO
WO12103419 Aug 2012 WO
WO13158189 Oct 2013 WO
Non-Patent Literature Citations (46)
Entry
PCT/US2015/014766 International Search Report and Written Opinion, dated Nov. 5, 2015.
PCT/US2004/042081: Search Report and Written Opinion.
PCT/US2005/000322: Search Report and Written Opinion.
PCT/US2008/053540: Search Report and Written Opinion.
PCT/US2008/053541: Search Report and Written Opinion.
PCT/US2008/059358: Search Report and Written Opinion.
PCT/US2009/036461: Search Report and Written Opinion.
PCT/US2010/032516: Search Report and Written Opinion.
PCT/US2010/032526: Search Report and Written Opinion.
PCT/US2010/032543: Search Report and Written Opinion.
PCT/US2010/032560: Search Report and Written Opinion.
PCT/US2010/032567: Search Report and Written Opinion.
PCT/US2010/032666: Search Report and Written Opinion.
PCT/US2010/032671: Search Report and Written Opinion.
PCT/US2010/032675: Search Report and Written Opinion.
PCT/US2010/032682: Search Report and Written Opinion.
PCT/US2010/032719: Search Report and Written Opinion.
PCT/US2013/023637: Search Report and Written Opinion.
Baker et al., “Evaluation of Specific Absorption Rates as a Dosimeter of MRI-Related Implant Heating”, Journal of Magnetic Resonance Imaging 20:315-320 (2004).
Baker, K., et al., “Neurostimulation Systems: Assessment of Magnetic Field Interactions Associated with 1.5 and 3-Tesla MR Systems”, J. Magn. Reson. Imaging, Jan. 2005, 21(1);72-7.
Chung, D.D.L., “Carbon Fiber Composites”, 1994, chapter 1, p. 8, table 1.2, Elsevier, ISBN: 978-0-7506-9169-7.
Chung, D.D.L., Comparison of Submicron-Diameter Carbon Filaments and Conventional Carbon Fibers as Fillers in Composite Materials, Carbon 39 (2001) pp. 1119-1125, Elsevier Science Ltd.
Chung, D.D.L., Electromagnetic Interference Shielding Effectiveness of Carbon Materials, Carbon 29 (2001) pp. 279-285, Elsevier Science Ltd.
Engdahl, Tomi, “Ground Loop Basics.” Web Jan. 4, 2009, ePanorama.net www.epanorama.net/documents/groundloop/basics.html 28052.00 U.S. Appl. No. 11/739,787.
Finelli, D., et al., “MRI Imaging-Related Heating of Deep Brain Stimulation Electrodes: In Vitro Study”, AJNR AM. J. Neuroadiol 23:1, Nov./Dec. 2002.
Jou, W.S. “A Novel Structure of Woven Continuous-Carbon Fiber Composites with High Electromagnetic Shielding”, Journal of Electronic Materials, vol. 33, No. 3, Mar. 1, 2004, pp. 162-170(9), Minerals, Metals and Materials Society, http://findarticles.com/p/articles/mi_au3776/is_200403/ai_n9405_582/print.
Kolin, et al., “An Electromagnetic Catheter Flow Meter for Determination of Blood Flow in Major Arteries,” Department of Biophysics, Physiology, and Radiology, University of California School of Medicine (Los Angeles) Jan. 19, 1988, Proc. N.A.S. vol. 59, pp. 808-815.
Kolin, et al., “An Electromagnetic Intravascular Blood-Flow Sensor”, Department of Biophysics, University of California School of Medicine (Los Angeles), Mar. 20, 1967, Proc. N.A.S., vol. 57, pp. 1331-1337.
Kolin, et al., “Miniaturization of the Electromagnetic Blood Flow Meter and Its Use for the Recording of Circulatory Responses of Conscious Animals to Sensory Stimuli”, Department of Biophysics, University of California at Los Angeles, Aug. 1959, Proc. N.A.S. vol. 45(8), pp. 1312-1321.
Medtronic Activa Product Family and Procedure Solution Brochure, Medtronic, Inc, 2001.
Medtronic Neurostimulation Systems Brochure, Medtronic, Inc., 2002.
Quick et al., “Endourethral MRI”, Magnetic Resonance in Medicine, 45:138-146, 2001.
Rezai, A., et al., “Neurostimulation System Used for Deep Brain Stimulation (DBS): MR Safety Issues and Implications of Failing to Follow Safety Recommendations” Investigative Radiology, May 2004, vol. 39, Issue 5, pp. 300-303.
Rezai, A., et al., “Neurostimulation Systems for Deep Brain Stimulation In Vitro Evaluation of Magnetic Resonance Imaging-Related Healing at 1.5 Tesla”, Journal of Magnetic Reson. Imaging 2002; 15:241-50.
U.S. Appl. No. 14/804,020, filed Jul. 20, 2015.
U.S. Appl. No. 14/804,020, Restriction Requirement, dated Apr. 20, 2016.
U.S. Appl. No. 14/804,020, Response filed Jun. 20, 2016.
U.S. Appl. No. 14/804,020 Non-Final Office Action dated Jul. 5, 2016.
U.S. Appl. No. 14/804,020, Response Filed Oct. 5, 2016.
U.S. Appl. No. 14/804,020, Non-Final Office Action dated Feb. 1, 2017.
U.S. Appl. No. 14/804,020, Response filed May 1, 2017.
U.S. Appl. No. 14/804,020, Final Office Action dated Jun. 26, 2017.
U.S. Appl. No. 14/804,020, Response filed Aug. 26, 2017.
U.S. Appl. No. 14/804,020, Advisory Action, dated Sep. 29, 2017.
U.S. Appl. No. 14/804,020, Response-Rce Request filed Sep. 25, 2017.
European Application No. 15 745 714.4-1124, EP Office Action Communication, dated Oct. 8, 2018.
Related Publications (1)
Number Date Country
20160022984 A1 Jan 2016 US
Provisional Applications (1)
Number Date Country
62028798 Jul 2014 US